Led · Series A · Aug 2026

BEYANG Therapeutics uses its ExCEED AI-powered molecular design platform to discover and develop differentiated small-molecule therapeutics. Its lead programs include BT01001, a non-invasive eye drop candidate for retinal diseases, and BT01002, a next-generation Menin inhibitor designed to overcome resistance in acute leukemia. The company plans to advance these programs through clinical development and expand its global R&D capabilities. BEYANG is positioning its platform-driven approach to accelerate drug discovery timelines and generate globally competitive assets. The recent Series A financing is intended to fund those development and expansion plans.

Led · Seed · Jan 2026

Fortitude Biomedicines is a private biotechnology company pioneering next-generation biologics that combine precise immune-cell targeting with molecular glue payloads to create more effective antibody-drug conjugates. Its proprietary GLUE-DACTM discovery engine, originating from research at Baylor College of Medicine, integrates ADC precision with targeted protein degradation to widen therapeutic windows, overcome resistance, and unlock new drug targets. The company’s lead immune-cell-targeting biologic is being advanced through IND-enabling studies, funded by its recently secured seed capital. Beyond this flagship candidate, Fortitude is building a broader pipeline aimed at oncology and autoimmune indications using the GLUE-DACTM platform. Headquartered in Waltham, Massachusetts, Fortitude was co-founded by serial entrepreneur Jesse Chen, Ph.D., and Baylor College of Medicine professor Jin Wang, Ph.D.; Chen now serves as president and CEO. The business is still pre-revenue and focused on preclinical research, with future milestones centered on submitting its first IND and expanding its ADC portfolio.

Participated · Equity · Jan 2026

Beijing-based Surgerii Robotics designs, manufactures, and markets laparoscopic surgical robotic systems and accessories, spearheaded by its flagship Shurui single-port endoscopic surgical robot (SR-ENS-600). The system employs snake-like, tele-operated instruments based on a Dual Continuum Mechanism developed at Shanghai Jiao Tong University, allowing complex procedures through one small incision. Shurui secured China NMPA clearance in June 2023 and CE marking in August 2025, becoming the first single-port robot approved for pediatric use and the second ever CE-certified platform after Intuitive’s da Vinci SP. Clinically, the company has partnered with more than 70 Grade A tertiary hospitals in China, supported over 3,000 surgeries, and enabled nearly 50 distinct procedures worldwide, developing 80+ new surgical techniques. Surgerii has also launched a European Clinical Excellence Center with IRCAD to drive adoption in high-end European markets. Future plans include accelerating international commercialization, expanding clinical applications, and developing next-generation energy instruments and other products. The recent $100 million financing fortifies its cash position to scale production, deepen domestic penetration, and enter additional global markets.

Participated · Series A · Dec 2025

Founded in 2021 in Suzhou by cardiovascular surgeon-scientist Dr. Qiu Xuefeng, Haimai Medical is building a tissue-engineering and regenerative medicine platform that preserves and optimizes the natural extracellular matrix to create “living” vascular grafts. Its two proprietary product lines are LineMatrix (a biological artificial graft) and CoroMatrix (a tissue-engineered graft), both positioned as the first of their kind in China. LineMatrix is the lead program and has already entered a multi-center registration clinical trial and the NMPA special review channel, with European clinical studies slated to begin next. Clinical data show a 100 % six-month cumulative patency rate versus <50 % for conventional ePTFE grafts. In 2024 the company commissioned a 2,243 m² C+-class GMP facility capable of producing more than 30,000 grafts annually. Over the past three years Haimai Medical has completed five funding rounds, enabling continued R&D and pipeline expansion toward broad cardiovascular applications.

Participated · Series C · Oct 2024

LaNova Medicines, founded in September 2019 and based in Shanghai, is a privately held clinical-stage biotech developing ADCs, bispecifics and monoclonal antibodies. Its pipeline includes six clinical-stage assets and more than ten preclinical programs, led by LM-302 (anti‑CLDN18.2 ADC), LM-108 (anti‑CCR8 mAb) and LM-299 (anti‑PD‑1/VEGF bispecific). LM-299 has entered a Phase I trial in China and LaNova expects to submit a U.S. IND in H2 2024. LM-302 is in a Phase III registrational trial in China with a planned U.S. Phase II start in H2 2025; LM-108 is in Phase II in China with planned U.S. Phase II and China Phase III milestones in H2 2024. The company emphasizes differentiated platform technologies for challenging targets and intends to advance its late-stage clinical programs toward registrational milestones. Recent financing proceeds will be used primarily to advance clinical development across the pipeline. LaNova Medicines completed a Series A financing in November 2020. The financing was led by Qiming Venture Partners, with China Renaissance acting as financial adviser. The announcement names additional investors including TF Capital, Yingke PE, Hony Capital, Biotrack Capital and YF Capital, among others. The article does not provide details on the company's product offerings, future plans, or operating metrics. The size of the Series A was not disclosed in the announcement. The announcement highlights Qiming Venture Partners' reputation, describing it as a top-tier VC firm with global recognition.